Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Pan, Xiaohui, Zhang, Wenxin, Guo, Hongjie, Cheng, Shuyuan, He, Qiaojun, Yang, Bo, Ding, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276686/
https://www.ncbi.nlm.nih.gov/pubmed/32528824
http://dx.doi.org/10.1016/j.apsb.2019.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276686/
https://www.ncbi.nlm.nih.gov/pubmed/32528824
http://dx.doi.org/10.1016/j.apsb.2019.09.006

Ejemplares similares